SAN JOSE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- Applied Imaging Corp. , or "Applied Imaging," today announced that Dr. John F. Reilly of Merck Research Laboratories will speak at International Business Communications' 11th Annual Drug Discovery Technology & Development World Congress on August 10, 2006 at the World Trade Center and the Seaport Hotel in Boston, MA.
In his presentation, entitled "Immunohistochemical Biomarkers for Responder Identification," Dr. Reilly will discuss his use of Applied Imaging's Ariol(R) automated imaging and image analysis system in the immunohistochemical analysis of cancer tissue microarrays (TMAs) to identify potential patient populations for new targeted cancer treatments.
"Biomarkers are becoming vital in identifying those patients who are likely to respond to a targeted therapeutic drug regimen," said Dr. Reilly. "The high image quality and advanced image analysis algorithms, coupled with automation, make the Applied Imaging Ariol system a great tool for quantitation of critical biomarkers in cancer patent tissue samples."
"We are delighted that Merck has selected the Ariol automated image analysis system for use in research that Dr. Reilly is conducting," said Robin Stracey, President and CEO of Applied Imaging. "We look forward to his presentation at this year's Drug Discovery Technology & Development World Congress and hope that his discussion will help highlight the growing role for automated systems like our Ariol platform in enhancing speed, accuracy and enriching data in drug research and development efforts."
Dr. Reilly's presentation will take place during the "Biomarkers: Utility, Validation and Applications from Discovery to Clinic" conference session on August 10 at 12:00 p.m. at the World Trade Center and the Seaport Hotel in Boston, MA.
To register for the conference, call (800) 390-4078 or firstname.lastname@example.org. To receive information about Dr. Reilly's presentation or to speak with Dr. Reilly, contact Saskia Sidenfaden at (310) 477-9800 x120 or Saskia.Sidenfaden@ccgir.com.
About Applied Imaging
Applied Imaging Corp., based in San Jose, California, is the leading supplier of automated imaging and image analysis systems for the detection and characterization of chromosomes and molecular markers in genetics and pathology applications. The Company develops, manufactures and markets a range of scanning and image analysis systems for both conventional (brightfield) and fluorescent microscopic analysis of cellular and tissue specimens. Products are sold to hospital laboratories, cancer centers, prenatal clinics and research institutions for both research and clinical purposes. The Company has installed over 4,000 of its systems in over 1000 laboratories in more than 60 countries around the world. Beyond its core business, through its wholly-owned subsidiary, CTC, Inc., the Company is also developing a system for the detection, quantification and characterization of tumor cells in the blood of cancer patients. For more about Applied Imaging Corp., visit www.aicorp.com.
For More Information:
CCG Investor Relations
Crocker Coulson, President
10960 Wilshire Boulevard, Suite 2050
Los Angeles, CA 90024
Applied Imaging Corp.
Terry Griffin, Chief Financial Officer
120 Baytech Drive,
San Jose, CA 95134
Applied Imaging Corp.
CONTACT: Crocker Coulson, President of CCG Investor Relations,+1-310-477-9800, email@example.com, for Applied Imaging Corp.; orTerry Griffin, Chief Financial Officer of Applied Imaging Corp.,+1-408-719-6417, firstname.lastname@example.org